Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

Loading...
Loading...
In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals
KERX
. Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.” Keryx Biopharmaceuticals closed on Tuesday at $2.93.
Posted In: Analyst ColorReiterationAnalyst RatingsDawson James Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...